

## Curriculum Vitae

**Kris C. Wood**

Associate Professor of Pharmacology and Cancer Biology  
Duke University

### CONTACT INFORMATION

450 Research Drive  
C134 LSRC, DUMC 3813  
Durham, NC 27710

Phone: (919) 613-8634  
kris.wood@duke.edu

### EDUCATION AND TRAINING

- 6/07-7/12 NIH Postdoctoral Fellow, Whitehead Institute for Biomedical Research, Cambridge, MA  
Broad Institute of Harvard and MIT and Howard Hughes Medical Institute  
Advisor: David M. Sabatini, M.D., Ph.D.
- 9/02-5/07 Ph.D., Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA  
Advisors: Paula T. Hammond, Ph.D. and Robert S. Langer, Sc.D.  
Minor: Cell Biology
- 8/98-5/02 B.S., Chemical Engineering, University of Kentucky, Lexington, KY  
*Summa Cum Laude* (GPA: 4.0/4.0, Class Rank: 1/30)

### PROFESSIONAL EXPERIENCE

- 8/12-Present Duke University, Durham, NC  
Associate Professor with tenure (2020-Present)  
Assistant Professor (2012-20)  
Department of Pharmacology and Cancer Biology, School of Medicine (primary)  
Department of Cell Biology, School of Medicine (secondary)  
Graduate program memberships: Molecular Cancer Biology, Pharmacology, Medical Scientist Training Program, Cell and Molecular Biology, University Program in Genetics and Genomics, Computational Biology and Bioinformatics, Biomedical Engineering
- 6/01-9/01 Massachusetts Institute of Technology, Cambridge, MA  
NSF Summer Undergraduate Research Fellow, Center for Materials Science and Engineering
- 5/00-5/01; University of Kentucky, Lexington, KY  
9/01-5/02 NSF Undergraduate Research Fellow, Department of Chemical Engineering

### SCHOLARSHIPS, FELLOWSHIPS, HONORS, AND PROFESSIONAL SERVICE

- 2021-23 Idea Development Award, DoD Lung Cancer Research Program  
2019-22 Breakthrough Expansion Award, DoD Breast Cancer Research Program  
2020-Present Associate Editor, *npg Precision Oncology*  
2016-2019 Breakthrough Award, DoD Breast Cancer Research Program  
2016-2017 Member, Board of Associate Scientific Advisors, *Science Translational Medicine*  
2015-2018 Liz Tilberis Early Career Award, Ovarian Cancer Research Fund  
2013-2015 V Scholar Award, V Foundation for Cancer Research  
2013-2015 Stewart Trust Fellowship  
2013-2017 Forbeck Scholar Award  
2013-2015 Lloyd Trust Translational Research Award

Last updated: 07/27/2023

2013-2014	Golfers Against Cancer Research Award
2013-2016	Whitehead Scholar Award
2012-2014	BIRCWH Scholar Award
2011-2012	Misrock Fund Postdoctoral Fellowship in Cancer Research
2008-2011	NIH Ruth L. Kirschstein National Research Service Award (F32)
2008-2011	American Cancer Society Postdoctoral Fellowship (declined)
2006-2007	Ludwig Graduate Fellowship in Molecular Oncology
2006	Materials Research Society Graduate Student Silver Award
2006	Outstanding Seminar Award, Chemical Engineering, MIT (Spring)
2002-2003	DuPont-MIT Fellowship
2002	University of Kentucky (UK) College of Engineering Tau Beta Pi Outstanding Senior Award
2002	UK Omega Chi Epsilon Outstanding Senior in Chemical Engineering Award
2001-2002	Barry M. Goldwater Scholarship for Science and Mathematics
2001	UK AIChE Outstanding Junior in Chemical Engineering Award
2000	UK AIChE Donald F. Othmer Sophomore Academic Excellence Award
1998	UK General Chemistry Award

## PUBLICATIONS (\* denotes corresponding author(s))

### Original research

1. Meyer, D.E.; **Wood, K.**; Bachas, L.G.; Bhattacharyya, D.\* (2004). Degradation of chlorinated organics by membrane-immobilized nanosized metals, *Environ. Prog.*, **23**, 232-242.
2. **Wood, K.C.**; Boedicker, J.Q.; Lynn, D.M.; Hammond, P.T.\* (2005). Tunable drug release from hydrolytically degradable layer-by-layer thin films, *Langmuir*, **21**, 1603-1609.
3. **Wood, K.C.**; Little, S.R.; Langer R.\*; Hammond, P.T.\* (2005). A family of hierarchically self-assembling linear-dendritic hybrid polymers for targeted efficient gene delivery, *Angew. Chem. Int. Ed.* **44**, 6704-6708.
4. **Wood, K.C.**; Chuang, H.F.; Batten, R.D.; Lynn, D.M.; Hammond, P.T.\* (2006). Controlling interlayer diffusion to achieve sustained, multi-agent drug delivery from layer-by-layer thin films," *Proc. Natl. Acad. Sci. USA* **103**, 10207-10212.
5. **Wood, K.C.**; Zacharia, N.S.; Schmidt, D.J.; Wrightman, S.; Andaya, B.J.; Hammond, P.T.\* (2008). Electroactive controlled release thin films, *Proc. Natl. Acad. Sci. USA* **105**, 2280-2285.
6. **Wood, K.C.**; Azarin, S.M.; Arap, W.; Pasqualini, R.; Langer, R.\*; Hammond, P.T.\* (2008). Tumor-targeted gene delivery using molecularly engineered hybrid polymers functionalized with a tumor-homing peptide, *Bioconjugate Chem.* **19**, 403-405.
7. **Wood, K.C.\***; Konieczkowski, D.J.; Johannessen, C.M.; Boehm, J.S.; Tamayo, P.; Botvinnik, O.B.; Mesirov, J.P.; Hahn, W.C.; Root, D.E.; Garraway, L.A.; Sabatini D.M.\* (2012). MicroSCALE screening reveals genetic modifiers of therapeutic response in melanoma, *Science Signaling* **5**, rs4.
8. Wood, K.B.; **Wood, K.C.**; Nishida, S.; Cluzel, P.\* (2014). Conservation laws for resistance to multi-drug treatments in microbes and human cancer cells, *Cell Reports* **6**, 1073.
9. Martz, C.A.<sup>¶</sup>; Ottina, K.A.<sup>¶</sup>; Singleton, K.S.<sup>¶</sup>; Jasper, J.S.; Wardell, S.E.; Peraza-Penton, A.; Anderson, G.R.; Winter, P.S.; Wang, T.; Alley, H.M.; Kwong, L.N.; Cooper, Z.A.; Tetzlaff, M.; Chen, P.-L.; Rathmell, J.C.; Flaherty, K.T.; Wargo, J.A.; McDonnell, D.M.; Sabatini, D.M.\*; **Wood, K.C.\*** (2014). Systematic identification of signaling pathways with potential to confer anticancer drug resistance, *Science Signaling* **7**, ra121. (<sup>¶</sup>Co-first authors)
10. Winter, P.S.; Sarosiek, K.A.; Lin, K.H.; Meggendorfer, M.; Schnittger, S.; Letai, A.; **Wood, K.C.\*** (2014). RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis, *Science Signaling* **7**, ra122.

11. Gerriets, V.A.; Kishton, R.J.; Nichols, A.G.; Macintyre, A.N.; Inoue, M.; Ilkayeva, O.; Winter, P.S.; **Wood, K.C.**; Liu, X.; Priyadharshini, B.; Slawinska, M.E.; Haeberli, L.; Huck, C.; Turka, L.A.; Hale, L.P.; Smith, P.A.; Schneider, M.A.; MacIver, N.J.; Locasale, J.W.; Newgard, C.B.; Shinohara, M.L.; Rathmell, J.C.\* (2014). Metabolic Programming and PDHK1 Control CD4 T-Cell Subsets and Inflammation, *J. Clin. Inv.* **125**(1):194-207.
12. Misale, S.<sup>¶</sup>; Bozic, I.<sup>¶</sup>; Tong, J.; Peraza-Penton, A.; Lallo, A.; Baldi, F.; Lin, K.H.; Truini, M.; Trusolino, L.; Bertotti, A.; Di Nicolantonio, F.; Nowak, M.A.; Zhang, L.; **Wood, K.C.**; Bardelli, A.\* (2015). Vertical suppression of the EGFR pathway delays onset of resistance in colorectal cancer models, *Nature Communications* **6**,8305-14. (<sup>¶</sup>Co-first authors)
13. Son, S.; Stevens, M.M.; Chao, H.X.; Thoreen, C.; Hosios, A.M.; Schweitzer, L.D.; Weng, Y.; **Wood, K.**; Sabatini, D.; Vander Heiden, M.G.; Manalis, S.\* (2015). Cooperative nutrient accumulation sustains growth of mammalian cells, *Sci. Rep.* **5**, 17401.
14. Park, S.; Chang, C.; Safi, R.; Liu, X.; Baldi, R.; Jasper, J.; Anderson, G.; Liu, T.; Rathmell, J.; Dewhirst, M.W.; **Wood, K.C.**; Locasale, J.W.; McDonnell, D.P.\* (2016). ERR $\alpha$  regulated lactate metabolism contributes to resistance to targeted therapies in breast cancer, *Cell Reports* **15**(2), 323-335.
15. Cribb, J.; Osborne, L.D.; Beicker, K.; Psioda, M.; Chen, J.; O'Brien, E.T.; Taylor II, R.M.; Vicci, L.; Hsiao, J.P.L.; Shao, C.; Falvo, M.; Ibrahim, J.G.; **Wood, K.C.**; Blobe, G.C.; Superfine, R.\* (2016). An Automated High-throughput Array Microscope for Cancer Cell Mechanics, *Sci. Rep.* **6**, 27371.
16. Lin, K.H.; Winter, P.S.; Xie, A.; Roth, C.; Martz, C.A.; Stein, E.M.; Anderson, G.R.; Tingley, J.P.; **Wood, K.C.**\* (2016) Targeting MCL-1/BCL-X<sub>L</sub> forestalls the acquisition of resistance to ABT-199 in acute myeloid leukemia *Sci. Rep.* **6**, 27696.
17. Anderson, G.R.; Wardell, S.E.; Cakir, M.; Crawford, L.; Leeds, J.C.; Nussbaum, D.N.; Shankar, P.S.; Soderquist, R.S.; Stein, E.M.; Tingley, J.P.; Winter, P.S.; Zeiser-Misenheimer, E.K.; Alley, H.M.; Yllanes, A.; Haney, V.; Blackwell, K.L.; McCall, S.J.; McDonnell, D.P.; **Wood, K.C.**\* (2016). *PIK3CA* mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation, *Science Translational Medicine* **8**, 369ra175.
18. Price, A.M.; Dai, J.; Bazot, Q.; Patel, L.; Nikitin, P.A.; Djavadian, R.; Winter, P.S.; Salinas, C.A.; Perkins Barry, A.; **Wood, K.C.**; Johannsen, E.C.; Letai, A.; Allday, M.J.; Luftig, M.A.\* (2017). Epstein-Barr virus ensures B cell survival by uniquely modulating apoptosis at early and late times after infection, *eLife* **6**, e22509.
19. Ali, M.<sup>¶</sup>; Kaltenbrun, E.<sup>¶</sup>; Anderson, G.R.<sup>‡</sup>; Stephens, S.J.<sup>‡</sup>; Arena, S.; Bardelli, A.; Counter, C.M.\*; **Wood, K.C.**\* (2017). Codon bias imposes a targetable limitation on *KRAS*-driven therapeutic resistance, *Nature Communications* **8**, 15617. (<sup>¶</sup>Co-first authors, <sup>‡</sup>Co-second authors)
20. Anderson, G.R.<sup>¶</sup>; Winter, P.S.<sup>¶</sup>; Lin, K.H.; Nussbaum, D.P.; Cakir, M.; Stein, E.M.; Soderquist, R.; Crawford, L.; Leeds, J.C.; Newcomb, R.; Stepp, P.; Yip, C.; Wardell, S.E.; Tingley, J.P.; Ali, M.; Xu, M.; Ryan, M.; McCall, S.J.; McRee, A.; Counter, C.M.; Der, C.J.; **Wood, K.C.**\* (2017). A landscape of therapeutic cooperativity in *KRAS* mutant cancers reveals principles for controlling tumor evolution, *Cell Reports* **20**, 999-1015. (<sup>¶</sup>Co-first authors)
21. Singleton, K.R.<sup>¶</sup>; Crawford, L.<sup>¶</sup>; Tsui, E.; Manchester, H.E.; Maertens, O.; Liu, X.; Liberti, M.V.; Magpusao, A.N.; Stein, E.M.; Tingley, J.P.; Frederick, D.T.; Boland, G.M.; Flaherty, K.T.; McCall, S.J.; Krepler, C.; Sproesser, K.; Herlyn, M.; Adams, D.J.; Locasale, J.W.; Cichowski, K.; Mukherjee, S.; **Wood, K.C.**\* (2017). Melanoma therapeutic strategies that select against resistance by exploiting MYC-driven evolutionary convergence, *Cell Reports* **21**, 2796-2812 (<sup>¶</sup>Co-first authors).
22. Crawford, L.A.\*; **Wood, K.C.**; Zhou, X.; Mukherjee, S.\* (2018). Bayesian approximate kernel regression with variable selection, *J. Am. Stat. Assoc.* **113**, 1710-1721.
23. Anderson, G.R.; Wardell, S.E.; Cakir, M.; Yip, C.; Ahn, Y.; Ali, M.; Yllanes, A.P.; Chao, C.A.; McDonnell, D.P.; **Wood, K.C.**\* (2018). Dysregulation of mitochondrial dynamics proteins are a targetable feature of human tumors, *Nature Communications* **9**, 1677.

24. Ohiri, K.A.; Kelly, S.T.; Motschman, J.D.; Lin, K.H.; **Wood, K.C.**; Yellen, B.B.\* (2018). A high throughput bulk acoustic wave device for the capture and compartmentalization of single cells, *Lab on a Chip* **18**, 2124-2133.
25. Soderquist, R.S.; Crawford, L.; Liu, E.; Lu, M.; Agarwal, A.; Anderson, G.R.; Lin, K.H.; Winter, P.S.; Cakir, M.; **Wood, K.C.**\* (2018). Systematic mapping of BCL-2 gene dependencies in cancer reveals molecular determinants of BH3 mimetic sensitivity, *Nature Communications* **9**, 3513.
26. Ding, Y.; Gong, C.; Huang, D.; Chen, R.; Sui, P.; Lin, K.H.; Liang, G.; Yuan, L.; Xiang, H.; Chen, J.; Yin, T.; Alexander, P.B.; Wang, Q.F.; Song, E.W.; Li, Q.-J.; **Wood, K.C.**\*; Wang, X.F.\* (2018). Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers, *Nature Communications* **9**, 4274.
27. Lin, K.H.<sup>¶</sup>; Xie, A.<sup>¶</sup>; Rutter, J.C.; Ahn, Y.; Lloyd-Cowden, J.M.; Nichols, A.G.; Soderquist, R.S.; Koves, T.R.; Muoio, D.; MacIver, N.J.; Lamba, J.; Pardee, T.S.; McCall, C.M.; Rizzieri, D.A.; **Wood, K.C.**\* (2019). Systematic dissection of the metabolic-apoptotic interface in AML reveals heme biosynthesis to be a regulator of therapeutic sensitivity, *Cell Metabolism* **29**, 1217-1231. (¶Co-first authors; May 2019 journal cover article)
28. Armstrong, A.J.\*; Gupta, S.; Healy, P.; Kemeny, G.; Leith, L.; Zalutsky, M.R.; Spritzer, C.; Davies, C.; Rothwell, C.J.; Ware, K.E.; Somarelli, J.; **Wood, K.**; Riber, T.; Giannakakou, P.; Zhang, J.; Gerber, D.; Anand, M.; Foo, W.-C.; Halabi, S.; Gregory, S.G.; George, D.J. (2019) Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer, *PLoS ONE* **14**, e0216934.
29. Cakir, M.; Mukherjee, S.\*; **Wood, K.C.**\* (2019). Label propagation defines signaling networks associated with recurrently mutated cancer genes, *Sci. Rep.* **9**, 9401.
30. Zhong, Z.; Sepramaniam, S.; Chew, X.H.; **Wood, K.**; Lee, M.A.; Madan, B.; Virshup, D.M.\* (2019). PORCN inhibition synergizes with PI3K/mTOR inhibition in Wnt-addicted cancers, *Oncogene* **38**, 6662.
31. Manzari, M.T.; Anderson, G.R.; Lin, K.H.; Soderquist, R.S.; Cakir, M.; Zhang, M.; Moore, C.E.; Skelton, R.N.; Fevre, M.; Li, X.; Bellucci, J.J.; Wardell, S.E.; Costa, S.A.; **Wood, K.C.**\*; Chilkoti, A.\* (2019). Genomically informed small molecule drugs overcome resistance to a sustained release formulation of an engineered death receptor agonist in patient-derived tumor models, *Science Advances* **5**, eaaw9162. (\*Co-corresponding authors)
32. Liberti, M.V.; Allen, A.; Singleton, K.R.; Guo, Z.; Liu, J.O.; **Wood, K.C.**; Locasale, J.W.\* (2019). Evolved resistance to partial GAPDH inhibition results in loss of the Warburg Effect and in a different state of glycolysis, *J Biol Chem* **295**, 111-124.
33. Lin, K.H.<sup>¶</sup>; Rutter, J.C.<sup>¶</sup>; Xie, A.; Pardieu, B.; Winn, E.T.; Dal Bello, R.; Forget, A.; Itzykson, R.; Ahn, Y.-R.; Dai, Z.; Sobhan, R.T.; Anderson, G.R.; Singleton, K.R.; Decker, A.E.; Winter, P.S.; Locasale, J.W.; Crawford, L.; Puissant, A.\*; **Wood, K.C.**\* (2020). Using antagonistic pleiotropy to design a chemotherapy-induced evolutionary trap to target drug resistance in cancer, *Nature Genetics* **52**, 408-417. (¶co-first authors, \*co-corresponding authors). (Commentary: Lin, C.Y.\* (2020). Springing an evolutionary trap on cancer, *Nature Genetics* **52**, 361-362.)
34. Ozkan-Dagliyan, I.; Diehl, J.N.; George, S.D.; Schaefer, A.; Papke, B.; Klotz-Noack, K.; Waters, A.M.; Goodwin, C.M.; Gautam, P.; Pierobon, M.; Peng, S.; Gilbert, T.S.K.; Lin, K.H.; Dagliyan, O.; Wennerberg, K.; Petricoin, E.F.; Tran, N.L.; Bhagwat, S.V.; Tiu, R.V.; Peng, S.B.; Herring, L.E.; Graves, L.M.; Sers, C.; **Wood, K.C.**; Cox, A.D.; Der, C.J.\* (2020). Low-dose vertical inhibition of the RAF-MEK-ERK cascade causes apoptotic death of *KRAS* mutant cancers, *Cell Reports* **31**, 107764.
35. Su, A.<sup>¶</sup>; Ling, F.<sup>¶</sup>; Vaganay, C.; Sodaro, G.; Benaksas, C.; Del Bello, R.; Forget, A.; Benajiba, L.; Pardieu, B.; Lin, K.H.; Rutter, J.C.; Bassil, C.F.; Fortin, G.; Pasanisi, J.; Antony-Debre, I.; Alexe, G.; Benoist, J.-F.; Pruvost, A.; Pikman, Y.; Qi, J.; Schlageter, M.H.; Micol, J.B.; Roti, G.; Cluzeau, T.; Dombret, H.; Preudhomme, C.; Fenouille, N.; Golan, H.M.; Stegmaier, K.; Lobry, C.\*; **Wood, K.C.**\*; Itzykson, R.\*; Puissant, A.\* (2020). The folate cycle enzyme MTHFR is a critical regulator of cell response to MYC-targeting therapies, *Cancer Discovery* **10**, 1894-1911. (¶¶Co-first authors; \*Co-senior authors).

- (Commentary: Marando, L.; Huntly, B.J.P.\* (2020). BETs need greens: Folate deficiency and resistance to MYC-targeted therapies, *Cancer Discovery* **10**, 1791-1793.)
36. Yellen, B.B.\*; Zawistowski, J.S.; Czech, E.A.; Sanford, C.I.; SoRelle, E.D.; Luftig, M.A.; Forbes, Z.G.; **Wood, K.C.\***; Hammerbacher, J.\* (2021) Massively parallel quantification of phenotypic heterogeneity in single cell drug responses, *Science Advances* **7**, eabf9840 (\*Co-corresponding authors).
  37. Joh, D.Y.<sup>¶</sup>; Heggestad, J.T.<sup>¶</sup>; Zhang, S.<sup>¶</sup>; Anderson, G.R.; Bhattacharyya, J.; Wardell, S.E.; Wall, S.A.; Cheng, A.B.; Albarghouthi, F.; Liu, J.; Oshima, S.; Hucknall, A.M.; Hyslop; Hall, A.H.S.; **Wood, K.C.**; Hwang, E.S.; Strickland, K.C.; Wei, Q.\*; Chilkoti, A.\* (2021) Cellphone enabled point-of-care assessment of breast tumor cytology and molecular HER2 expression from fine-needle aspirates, *npj Breast Cancer* **7**, 85 (<sup>¶</sup>Co-first authors; \*Co-senior authors).
  38. Luttmann, J.H.; Hoj, J.P.; Lin, K.H.; Lin, J.; Gu, J.J.; Rouse, C.; Nichols, A.G.; MacIver, N.J.; **Wood, K.C.**; Pendergast, A.M.\* (2021). ABL allosteric inhibitors synergize with statins to enhance apoptosis of metastatic lung cancer cells, *Cell Reports* **37**, 109880.
  39. Garcia, N.; Del Pozo, V.; Yohe, M.E.; Goodwin, C.M.; Shackelford, T.J.; Wang, L.; Baxi, K.; Chen, Y.; Rogojina, A.T.; Zimmerman, S.M.; Peer, C.J.; Figg, W.D.; Ignatius, M.S.; **Wood, K.C.**; Houghton, P.J.; Vaseva, A.V.\* (2021). Vertical inhibition of the RAF-MEK-ERK cascade induces myogenic differentiation, apoptosis, and tumor regression in H/NRAS Q61X-mutant rhabdomyosarcoma, *Mol. Cancer Ther.* **21**, 170-183.
  40. Javaid, S.; Schaefer, A.; Goodwin, C.M.; Nguyen, V.V.; Massey, F.L.; Pierobon, M.; Gambrell-Sanders, D.; Waters, A.M.; Lambert, K.N.; Hobbs, A.G.; Huynh, M.V.; **Wood, K.C.**; Petricoin, E.F.; Der, C.J.; Cox, A.D.\* (2022). Concurrent ERK inhibition blocks farnesyltransferase inhibitor-induced epithelial-to-mesenchymal transition to suppress the growth of *HRAS* mutant head and neck squamous cell carcinoma, *Mol. Cancer Ther.* **21**, 762-774.
  41. Zhong, Z.; Harmston, N.; **Wood, K.C.**; Madan, B.; Virshup, D.M.\* (2022). A p300/GATA6 axis determines differentiation and Wnt dependency in pancreatic cancer models, *J. Clin. Inv.* **132**, e156305.
  42. Ali, M.; Lu, M.; Ang, H.X.; Soderquist, R.S.; Eyler, C.E.; Hutchinson, H.M.; Glass, C.; Bassil C.F.; Lopez, O.M.; Kerr, D.; Falcon, C.J.; Yu, H.A.; Hata, A.N.; Blakely, C.M.; McCoach, C.E.; Bivona, T.G.; **Wood, K.C.\*** (2022). Small molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cells, *Science Translational Medicine* **14**, eabc7480.
  43. Lin, K.H.<sup>¶</sup>; Rutter, J.C.<sup>¶</sup>; Xie, A.; Killarney, S.T.; Vaganay, C.; Benaksas, C.; Ling, F.; Sodaro, G.; Meslin, P.A.; Bassil, C.F.; Fenouille, N.; Hoj, J.P.; Washart, R.; Ang, H.X.; Cerda-Smith, C.G.; Chaintreuil, P.; Jacquell, A.; Auberger, P.; Forget, A.; Itzykson, R.; Lu, M.; Lin, J.; Pierobon, M.; Sheng, Z.; Li, X.; Chilkoti, A.; Owzar, K.; Rizzieri, D.A.; Pardee, T.S.; Benajiba, L.; Petricoin, E.; Puissant, A.\*; **Wood, K.C.\*** (2022). P2RY2-AKT activation is a critical actionable consequence of nuclear export inhibition in acute myeloid leukemia, *Nature Cancer* **3**, 837-851. (<sup>¶</sup>Co-first authors; \*Co-corresponding authors). (Commentary: Gollner, S.\*; Muller-Tidow, C.\* (2022). AKTing on XPO1 inhibition in AML, *Nature Cancer* **3**, 787-789.)
  44. Kishton, R.J.\*; Patel, S.J.; Decker, A.E.; Vodnala, S.K.; Cam, M.; Yamamoto, T.N.; Patel, Y.; Sukumar, M.; Yu, Z.; Ji, M.; Henning, A.N.; Gurusamy, D.; Palmer, D.C.; Stefanescu, R.A.; Girvin, A.T.; Lo, W.; Pasetto, A.; Malekzadeh, P.; Deniger, D.C.; **Wood, K.C.**; Sanjana, N.E.; Restifo, N.P.\* (2022). Cancer genes disfavoring T cell immunity identified via integrated systems approach, *Cell Reports* **40**, 111153.
  45. Lidsky, M.E.<sup>¶</sup>\*; Wang, Z.<sup>¶</sup>; Lu, M.; Liu, A.; Hsu, S.D.; McCall, S.J.; Sheng, Z.; Granek, J.A.; Owzar, K.; Anderson, K.S.; **Wood, K.C.\*** (2022). Leveraging unique patient-derived models of *FGFR2* fusion-positive intrahepatic cholangiocarcinoma to identify novel synergistic therapies, *npj Precision Oncology* **6**, 75. (<sup>¶</sup>Co-first authors; \*Co-corresponding authors).
  46. Ahmad, S.; **Wood, K.C.**; Scott, J.E.\* (2022). A high throughput proliferation and cytotoxicity assay for co-cultured isogenic cell lines, *MethodsX* **9**, 101927. (PMID 36438856).
  47. Goodwin, C.M.; Waters, A.M.; Klomp, J.E.; Javaid, S.; Bryant, K.L.; Stalneck, C.A.; Drizyte-Miller, K.; Papke, B.; Yang, R.; Amparo, A.M.; Ozkan-Dagliyan, I.; Baldelli, E.; Calvert, V.; Pierobon, M.; Sorrentino,

Last updated: 07/27/2023

- J.A.; Beelen, A.P.; Bublitz, N.; Lüthen, M.; **Wood, K.C.**; Petricoin, E.F.; Sers, C.; McRee, A.J.; Cox, A.D.; Der, C.J.\* (2022). Combination therapies with CDK4/6 inhibitors to treat KRAS mutant pancreatic cancer, *Cancer Res.* **83**, 141-157. (PMID 36346366).
48. Mayro, B.; Hoj, J.P.; Cerda-Smith, C.G.; Hutchinson, H.M.; Caminear, M.W.; Thrash, H.L.; Winter, P.S.; Wardell, S.E.; McDonnell, D.P.; Wu, C.; **Wood, K.C.**; Pendergast, A.M.\* (2023). ABL kinases regulate the stabilization of HIF-1a and MYC through CPSF1, *Proc. Natl. Acad. Sci. USA* **120**, e2210418120.
49. Killarney, S.T.; Washart, R.; Soderquist, R.S.; Hoj, J.P.; Lebhar, J.; Lin, K.H.; **Wood, K.C.**\* (2023). Executioner caspases restrict mitochondrial RNA-driven Type I IFN induction during chemotherapy-induced apoptosis, *Nature Communications* **14**, 1399.
50. Stanland, L.J.; Ang, H.X.; Hoj, J.P.; Chu, Y.; Tan, P.; **Wood, K.C.**; Luftig, M.A.\* (2023). CBF-beta mitigates PI3K-alpha specific inhibitor killing through PIM1 in *PIK3CA* mutant gastric cancer (In press, *Mol. Cancer Res.*).
51. Ang, H.X.; Sutiman, N.; Deng, X.L.; Liu, A.; Cerda-Smith, C.G.; Hutchinson, H.M.; Kim, H.; Bartelt, L.C.; Chen, Q.; Barrera, A.; Lin, J.; Shen, Z.; McDowell, I.C.; Reddy, T.E.; Nicchitta, C.V.\*; **Wood, K.C.**\* (2023). Cooperative regulation of coupled oncoprotein synthesis and stability in triple-negative breast cancer by EGFR and CDK12/13 (In press, *Proc. Natl. Acad. Sci. USA*).

### Reviews and commentaries

1. **Wood, K.C.**; Sabatini, D.M.\* (2009). Growth signaling at the nexus of stem cell life and death, *Cell Stem Cell* **5**, 232-234.
2. **Wood, K.C.**\* (2015). Mapping the pathways of resistance to targeted therapies, *Cancer Res.* **75**, 4247-51.
3. **Wood, K.C.**\* (2016). Intercepting reversible drug tolerance to improve targeted therapy, *Science Translational Medicine* **8**, 332ec52.
4. **Wood, K.C.**\* (2016). Collaborating tumor cells overcome multitargeted antiangiogenic therapies, *Science Translational Medicine* **8**, 338ec77.
5. **Wood, K.C.**\* (2016). Targeting the cancer cells that just won't go away, *Science Translational Medicine* **8**, 344ec101.
6. **Wood, K.C.**\* (2016). Mapping a path for precision cancer therapies, *Science Translational Medicine* **8**, 348ec115.
7. **Wood, K.C.**\* (2016). Two faces of circulating breast cancer cells, *Science Translational Medicine* **8**, 356ec149.
8. Singleton, K.R.; **Wood, K.C.**\* (2016). Narrowing the focus: A toolkit to systematically connect oncogenic signaling pathways with cancer phenotypes, *Genes Cancer* **7**(7-8), 218-228.
9. **Wood, K.C.**\* (2016). Hacking T cells with synthetic circuits to program antitumor responses, *Science Translational Medicine* **8**, 362ec172.
10. **Wood, K.C.**\* (2016). An EXITS strategy for decreasing cancer risk in women, *Science Translational Medicine* **8**, 368ec197.
11. **Wood, K.C.**\* (2017). Suppressing oncogenic transcription with a little healthy competition, *Science Translational Medicine* **9**, 374aa15000.
12. Winter, P.S.; **Wood, K.C.**\* (2018). Mapping effector-phenotype landscapes in KRAS-driven cancers, *Trends in Cancer* **4**, 333-335.
13. **Wood, K.C.**\* (2020). Overcoming MCL-1-driven adaptive resistance to targeted therapies, *Nature Communications* **11**, 531.
14. **Wood, K.C.**\* (2022). Drivers of intrinsic resistance, *Nature Chemical Biology*, **18**, 579-81.

Last updated: 07/27/2023

15. **Wood, K.C.\***; Gutkind, J.S.\* (2022). Challenges and emerging opportunities in targeting mTOR in cancer, *Cancer Research* **82**, 3884-3887.
16. Sarosiek, K.A.\*; **Wood, K.C.\*** (2023). Endogenous and imposed determinants of apoptotic vulnerabilities in cancer, *Trends in Cancer* **9**, 96-110.
17. Killarney, S.T.; Tait, S.W.G.; Green, D.R.\*; **Wood, K.C.\*** (2023). Sublethal engagement of apoptotic pathways in residual cancer, *Trends in Cell Biology* (In press).

## EXTERNAL INVITED TALKS

### As a graduate student or postdoctoral fellow:

1. University of Texas-M.D. Anderson Cancer Center, Dept. of Genitourinary Medical Oncology, 2006.
2. University of California-Berkeley, Dept. of Chemical Engineering, 2007 (Dept. Seminar).
3. Georgia Institute of Technology, Dept. of Chemical Engineering, 2007 (Dept. Seminar).
4. MIT, Dept. of Chemistry, 2008 (Small Talks Seminar Series).
5. MIT, Dept. of Electrical Engineering and Computer Science, 2008 (MEMS@MIT Spring Symposium).
6. Broad Institute of Harvard and MIT, 2009 (Annual Meeting of the Board of Scientific Counselors).
7. Broad Institute of Harvard and MIT, 2009 (Annual Scientific Retreat).
8. Ohio State University, Dept. of Chemical and Biomolecular Engineering, 2012 (Dept. Seminar).
9. University of Virginia, Dept. of Biomedical Engineering, 2012 (Dept. Seminar).
10. University of Pennsylvania, Dept. of Bioengineering, 2012 (Dept. Seminar).
11. Washington University School of Medicine, Dept. of Genetics, 2012 (Dept. Seminar).
12. Harvard Medical School, Massachusetts General Hospital, Dept. of Pathology, 2012 (Dept. Seminar).
13. Duke University, Dept. of Pharmacology and Cancer Biology, 2012 (Dept. Seminar).

### As a faculty member:

14. Institute for Biological Engineering Annual Meeting, Raleigh, NC, 2013.
15. Forbeck Scholars Retreat, Hilton Head, SC, 2013.
16. University of North Carolina-Chapel Hill, Dept. of Pharmacology, Chapel Hill, NC, 2014.
17. University of Texas Medical Branch-Galveston, Dept. of Pharmacology, Galveston, TX, 2014.
18. National Cancer Institute-Frederick, Ras Program, Frederick, MD, 2014.
19. Dana-Farber Cancer Institute, Bone Marrow Transplant Grand Rounds, Boston, MA, 2014.
20. Whitehead Institute for Biomedical Research, Fall Whitehead Forum Seminar Series, Cambridge, MA, 2014.
21. UNC-Chapel Hill, Lineberger Comprehensive Cancer Center Fall Seminar Series, Chapel Hill, NC, 2014.
22. American Association for Cancer Research (AACR) Annual Meeting, Phenotypic Screening for Optimizing Cancer Therapy, Philadelphia, PA, 2015.
23. UNC/HHMI Translational Medicine Symposium, Keynote address, Chapel Hill, NC, 2015.
24. Mount Sinai School of Medicine, Dept. of Oncological Sciences, New York, NY, 2015.
25. *The Scientist* Webinar: Tools and Strategies to Study Cell Signaling Pathways, 2015 (virtual).
26. Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, 2016.
27. 40th Annual UNC Lineberger Cancer Center Symposium, "Molecularly targeted therapies from bench to bedside", Chapel Hill, NC, 2016.
28. American Association for Cancer Research (AACR) Annual Meeting, State of the Art Approaches to Study Resistance to Targeted Therapies, New Orleans, LA, 2016.
29. University of Pennsylvania, Abramson Family Cancer Research Institute and the Department of Hematology/Oncology, Philadelphia, PA, 2016.
30. American Association for Cancer Research (AACR) Precision Medicine Series: Opportunities and Challenges of Exploiting Synthetic Lethality in Cancer, San Diego, CA, 2017.
31. New York University, Laura and Isaac Perlmutter Cancer Center, Research Seminar Series, New York, NY, 2017.

*Last updated: 07/27/2023*

32. ASBMB Annual Meeting, Cancer Signaling and Therapeutics section, Chicago, IL, 2017.
33. 32<sup>nd</sup> Aspen Cancer Conference, Aspen, CO, 2017.
34. Pfizer Oncology, La Jolla, CA, 2017.
35. Center for Cell Reprogramming at Georgetown University Medical Center, Research Seminar Series, Washington, DC, 2018.
36. National Institute of Environmental Health Sciences (NIEHS), Receptor Mechanisms Discussion Group (RMDG), Research Triangle Park, NC, 2018.
37. Ludwig Institute, Harvard Medical School, Boston, MA, 2018.
38. UCSF Helen Diller Family Comprehensive Cancer Center Friday Seminar, San Francisco, CA, 2018.
39. University of California, San Diego, Cancer Center Genomics Program Research Seminar, La Jolla, CA, 2018.
40. Broad Institute of Harvard and MIT, Innovators in Cancer Seminar Series, Cambridge, MA, 2018.
41. Moffitt Cancer Center, Basic Science Grand Rounds, Tampa, FL, 2019.
42. Venetian Institute of Molecular Medicine, University of Padova, Italy, 2019.
43. NCI Physical Sciences-Oncology Network (PS-ON) and Cancer Systems Biology Consortium (CSBC) Annual Junior Investigators' Meeting (Keynote lecturer), Shady Grove, MD, 2019.
44. Cold Spring Harbor Laboratory Meeting: Cell Death, Cold Spring Harbor, NY, 2019.
45. Quantitative Biology of the Cancer Cell Symposium, UCSF/UCSD Cancer Cell Mapping Initiative, San Francisco, CA, 2020.
46. Sixth AACR-IASLC International Joint Conference: Lung Cancer Translational Science from the Bench to the Clinic, San Diego, CA, 2020.
47. LabRoots 8<sup>th</sup> Annual Genetics Virtual Week, Precision Medicine Symposium, 2020 (virtual).
48. St. Jude Children's Research Hospital, Dept. of Cell and Molecular Biology, Memphis, TN, 2020 (virtual).
49. Dana-Farber / Harvard Cancer Center (DFHCC) Connect:Science Seminar Series, Boston, MA, 2020 (virtual).
50. Virtually Dead Episode I: Mitochondria Symposium, 2020 (virtual).
51. Peter MacCallum Cancer Centre Seminar Series, Melbourne, Australia, 2021 (virtual).
52. Syros Pharmaceuticals, Cambridge, MA, 2021 (virtual).
53. V Scholar Summit, Speaker and panelist, SAS Institute, Raleigh, NC, 2021 (virtual).
54. AACR Annual Meeting, Session on Therapy Resistance in Leukemia, 2021 (virtual).
55. Vanderbilt University, Dept. of Pathology, Microbiology, and Immunology, Nashville, TN, 2021 (virtual).
56. Vividion Therapeutics, San Diego, CA, 2021.
57. Forbeck Forum, Strategies to Overcome Heterogeneous Resistance Mechanisms, Denver, CO, 2021.
58. LabRoots CRISPR 2022, 2022 (virtual).
59. Tel Aviv University, Department of Human Molecular Genetics and Biochemistry, Tel Aviv, Israel, 2023.
60. Hebrew University, Department of Biochemistry and Molecular Biology, Jerusalem, Israel, 2023.
61. Weizmann Institute of Science, Department of Molecular Cell Biology, Rehovot, Israel, 2023.